Race Oncology (ASX:RAC) has announced that the investigator-sponsored Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine in relapsed or refractory acute myeloid leukaemia patients has been successfully concluded having achieved its primary endpoint for efficacy.
Race Oncology says Phase 2 trial of Bisantrene meets predetermined efficacy criteria
July 30, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 5 September
September 5, 2025 - - Podcast -
Novartis ANZ appoints Marco Muscardo as ad-interim Country PresidentÂ
September 4, 2025 - - Latest News -
Australian industry looks to the UK as likely lesson for US 'Most Favored Nation'
September 4, 2025 - - Latest News -
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 - - Latest News -
The latest HTA Review report is a Dickensian tribute to policymaking and reform
September 3, 2025 - - Latest News -
Stakeholders could be mistaken for thinking the process is the point
September 3, 2025 - - Latest News -
Regulate the regulators - Why NDIS audit fees are failing providers and participants
September 3, 2025 - - Latest News